Clinical and molecular biologic characteristics of 36 cases of leukemia with 11q23/mll.
- Author:
Jie ZHAO
1
;
Yu-Ming YIN
;
Yan-Li ZHAO
;
Yuan SUN
;
Jing-Bo WANG
;
Jing ZHONG
;
Xian ZHANG
;
Xin-Hong FEI
;
Fu-Xiang SHAN
;
Hong-Xing LIU
;
Tong WANG
;
Hui WANG
;
Chun-Rong TONG
;
Tong WU
;
Dao-Pei LU
Author Information
1. Beijing Daopei Hospital, Beijing 100049, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Child;
Child, Preschool;
Female;
Hematopoietic Stem Cell Transplantation;
Histone-Lysine N-Methyltransferase;
Humans;
Infant;
Leukemia;
classification;
diagnosis;
genetics;
therapy;
Leukemia, Myeloid, Acute;
diagnosis;
genetics;
therapy;
Male;
Middle Aged;
Myeloid-Lymphoid Leukemia Protein;
genetics;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
genetics;
therapy;
Prognosis;
Survival Rate;
Young Adult
- From:
Journal of Experimental Hematology
2010;18(6):1381-1385
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to analyze the clinical and cytogenetic characteristics of acute leukemia with 11q23/mll rearrangement and explore the reasonable therapeutic principles. Characteristics in general situation, morphology, immunology, molecular biology, cytogenetics, treatment and overall survival of 36 cases of acute leukemias with mll gene rearrangement were studied and analyzed. The results showed that 36 cases with mll gene rearrangement were found positive (7.2%) in 494 patients with acute leukemia. Among the 36 cases of mll rearrangement positive, 32 cases were diagnosed as acute myeloid leukemia (AML) with myeloid antigen expression, of which 5 cases expressed lymphoblastic differentiation antigen; 4 cases were classified as B-lineage acute lymphoblastic leukemia (ALL), of which non-lineage myeloid expression pattern were found in 3 cases. In 29 out of 36 cases (80%) the clonal chromosomal aberration were detected, of which chromosome 11 aberration were observed in 22 cases. All patients received chemotherapy with a total response rate of 47.2%. Of the responded patients, 10 cases relapsed within 6 months, with a recurrence rate of 40%; 9 cases received hematopoietic stem cell transplantation (HSCT), 7 cases of which survived after transplantation. The median survival time of 36 cases was 16 months (range 2 - 46) and their 2-year overall survival rate was 41.4%. The 2-year overall survival rate of 9 patients who received HSCT was 87.5%. It is concluded that acute leukemia patients with mll gene rearrangement show poor response to chemotherapy, high recurrence rate and poor prognosis. Hematopoietic stem cell transplantation may be a reasonable treatment principle to improve these patients' survival situation.
